Learn why the VictoryShares Dividend Accelerator ETF (VSDA) has underperformed its peers and why it may not be the best ...
Bristol-Myers Squibb's stock price has risen more than 25% over the past six months, reflecting significant progress in its ...
We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...
21h
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bristol-Myers Squibb (BMY – Research Report) ...
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy programme, as per an 18 ...
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
Medpage Today on MSN16h
Spironolactone Misses the Mark in Acute MI Without HFOver 2 decades ago, the aldosterone antagonist eplerenone proved beneficial after MI complicated by left ventricular ...
Patients with GPA completely weaned off glucocorticoids were four times as likely to flare compared with those kept on a low ...
Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...
To access these pages you must be a permanent member of University staff and registered on the UoB domain. Staff who are unable to access these pages or need additional access to student data should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback